Logo image of GLPG.AS

GALAPAGOS NV (GLPG.AS) Stock Fundamental Analysis

AMS:GLPG - Euronext Amsterdam - BE0003818359 - Common Stock - Currency: EUR

24.3  +0.42 (+1.76%)

Fundamental Rating

3

Overall GLPG gets a fundamental rating of 3 out of 10. We evaluated GLPG against 71 industry peers in the Biotechnology industry. GLPG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GLPG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year GLPG has reported negative net income.
GLPG had a negative operating cash flow in the past year.
In multiple years GLPG reported negative net income over the last 5 years.
In the past 5 years GLPG always reported negative operating cash flow.
GLPG.AS Yearly Net Income VS EBIT VS OCF VS FCFGLPG.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

1.2 Ratios

Looking at the Return On Assets, with a value of 1.79%, GLPG is in the better half of the industry, outperforming 76.06% of the companies in the same industry.
The Return On Equity of GLPG (2.56%) is better than 78.87% of its industry peers.
Industry RankSector Rank
ROA 1.79%
ROE 2.56%
ROIC N/A
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
GLPG.AS Yearly ROA, ROE, ROICGLPG.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

Looking at the Profit Margin, with a value of 25.35%, GLPG belongs to the top of the industry, outperforming 90.14% of the companies in the same industry.
In the last couple of years the Profit Margin of GLPG has grown nicely.
GLPG has a Gross Margin of 88.07%. This is amongst the best in the industry. GLPG outperforms 84.51% of its industry peers.
GLPG's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 25.35%
GM 88.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
GLPG.AS Yearly Profit, Operating, Gross MarginsGLPG.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

More info and screens

5

2. Health

2.1 Basic Checks

GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GLPG has about the same amount of shares outstanding.
The number of shares outstanding for GLPG has been increased compared to 5 years ago.
The debt/assets ratio for GLPG is higher compared to a year ago.
GLPG.AS Yearly Shares OutstandingGLPG.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLPG.AS Yearly Total Debt VS Total AssetsGLPG.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

GLPG has an Altman-Z score of 1.51. This is a bad value and indicates that GLPG is not financially healthy and even has some risk of bankruptcy.
GLPG's Altman-Z score of 1.51 is fine compared to the rest of the industry. GLPG outperforms 64.79% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that GLPG is not too dependend on debt financing.
GLPG has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. GLPG outperforms 91.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACCN/A
WACC7.94%
GLPG.AS Yearly LT Debt VS Equity VS FCFGLPG.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

GLPG has a Current Ratio of 9.97. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GLPG (9.97) is better than 95.77% of its industry peers.
GLPG has a Quick Ratio of 9.81. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 9.81, GLPG belongs to the best of the industry, outperforming 95.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.97
Quick Ratio 9.81
GLPG.AS Yearly Current Assets VS Current LiabilitesGLPG.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

GLPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -157.48%.
Measured over the past years, GLPG shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -12.47% on average per year.
Looking at the last year, GLPG shows a quite strong growth in Revenue. The Revenue has grown by 14.99% in the last year.
GLPG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.82% yearly.
EPS 1Y (TTM)-157.48%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-259.22%
Revenue 1Y (TTM)14.99%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%11.56%

3.2 Future

GLPG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -40.64% yearly.
The Revenue is expected to decrease by -1.23% on average over the next years.
EPS Next Y-198.38%
EPS Next 2Y-80.47%
EPS Next 3Y-70.29%
EPS Next 5Y-40.64%
Revenue Next Year-7.9%
Revenue Next 2Y-4.31%
Revenue Next 3Y-5.85%
Revenue Next 5Y-1.23%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
GLPG.AS Yearly Revenue VS EstimatesGLPG.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
GLPG.AS Yearly EPS VS EstimatesGLPG.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GLPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLPG.AS Price Earnings VS Forward Price EarningsGLPG.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLPG.AS Per share dataGLPG.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

A cheap valuation may be justified as GLPG's earnings are expected to decrease with -70.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-80.47%
EPS Next 3Y-70.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLPG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALAPAGOS NV

AMS:GLPG (5/2/2025, 7:00:00 PM)

24.3

+0.42 (+1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-23 2025-04-23/amc
Earnings (Next)07-23 2025-07-23
Inst Owners48.62%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap1.60B
Analysts49.47
Price Target30.95 (27.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.56%
Min EPS beat(2)-52.97%
Max EPS beat(2)154.1%
EPS beat(4)3
Avg EPS beat(4)329.61%
Min EPS beat(4)-52.97%
Max EPS beat(4)1052.58%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.66%
Min Revenue beat(2)-15.5%
Max Revenue beat(2)-11.82%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.37%
PT rev (3m)-9.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-92.83%
EPS NY rev (3m)-105.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1%
Revenue NY rev (3m)-3.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.48
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-2.43
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-6.1
FCFYN/A
OCF(TTM)-4.86
OCFYN/A
SpS4.44
BVpS43.96
TBVpS40.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.79%
ROE 2.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 25.35%
GM 88.07%
FCFM N/A
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 180.47%
Cap/Sales 28.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.97
Quick Ratio 9.81
Altman-Z 1.51
F-Score2
WACC7.94%
ROIC/WACCN/A
Cap/Depr(3y)93.66%
Cap/Depr(5y)187.37%
Cap/Sales(3y)17.05%
Cap/Sales(5y)15.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-157.48%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-259.22%
EPS Next Y-198.38%
EPS Next 2Y-80.47%
EPS Next 3Y-70.29%
EPS Next 5Y-40.64%
Revenue 1Y (TTM)14.99%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%11.56%
Revenue Next Year-7.9%
Revenue Next 2Y-4.31%
Revenue Next 3Y-5.85%
Revenue Next 5Y-1.23%
EBIT growth 1Y-121.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.37%
EBIT Next 3Y-21.96%
EBIT Next 5Y-15.13%
FCF growth 1Y5.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.17%
OCF growth 3YN/A
OCF growth 5YN/A